Drug Monograph

Drug/Drug Class: **Daklinza® (daclatasvir) tablet/ Hepatitis C Anti-viral Agent**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Daklinza® is now available in a tablet containing 90 mg daclatasvir.
Manufacturer:	Bristol-Myers Squibb Company, Princeton, NJ 08543
Indications:	Daklinza® is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus genotype 1 or genotype 3 infection.
Costs:	$757.50 per tablet of Daklinza®. Maximum Allowable Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Under Solicitation ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 16, 2016